Effect of zoledronic acid on serum calcium in Paget’s disease patients after educational strategies to improve calcium and vitamin D supplementation
Objective: Bisphosphonates are the most effective therapeutic agents in patients with Paget’s disease of bone. As a result of their inhibition of osteoclastic activity, hypocalcemia of variable frequency and severity following intravenous bisphosphonate therapy has been reported. The present study a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2015-08-01
|
| Series: | Therapeutic Advances in Endocrinology and Metabolism |
| Online Access: | https://doi.org/10.1177/2042018815579020 |
| _version_ | 1818937200895590400 |
|---|---|
| author | Joseph R. Tucci Henry G. Bone Guoqin Su Monique Tan Zafer E. Ozturk Paul Aftring |
| author_facet | Joseph R. Tucci Henry G. Bone Guoqin Su Monique Tan Zafer E. Ozturk Paul Aftring |
| author_sort | Joseph R. Tucci |
| collection | DOAJ |
| description | Objective: Bisphosphonates are the most effective therapeutic agents in patients with Paget’s disease of bone. As a result of their inhibition of osteoclastic activity, hypocalcemia of variable frequency and severity following intravenous bisphosphonate therapy has been reported. The present study assessed the effect of physician and patient education on adequate supplementation of calcium and vitamin D to reduce the potential risk of developing hypocalcemia following infusion of 5 mg zoledronic acid. Methods: This was an open-label, multicenter, controlled registry trial in which patients with Paget’s disease were treated with a single intravenous infusion of zoledronic acid. Physicians were provided with educational materials focusing on optimization of calcium and vitamin D supplementation following zoledronic infusion that they used to educate their patients. The primary safety variable was the percentage of patients with serum calcium level <2.07mmol/l 9–11 days after zoledronic acid infusion. Results: A total of 75 patients were evaluable in the post dose hypocalcemia safety analysis. Of these, only 1 patient had treatment-emergent hypocalcemia, with a serum calcium level of 1.92 mmol/l 4 days following therapy. Hypocalcemia-related symptoms were not reported in this patient and the serum calcium returned to normal range at 2.17 mmol/l within 1 week on oral calcium supplementation. Conclusions: These results suggest that, with optimization of calcium and vitamin D supplementation by physician and patient education, hypocalcemia is an infrequent occurrence following zoledronic acid infusion. |
| first_indexed | 2024-12-20T05:48:11Z |
| format | Article |
| id | doaj.art-a912212faf3d4c18a488ffd8686b5aa7 |
| institution | Directory Open Access Journal |
| issn | 2042-0188 2042-0196 |
| language | English |
| last_indexed | 2024-12-20T05:48:11Z |
| publishDate | 2015-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Endocrinology and Metabolism |
| spelling | doaj.art-a912212faf3d4c18a488ffd8686b5aa72022-12-21T19:51:16ZengSAGE PublishingTherapeutic Advances in Endocrinology and Metabolism2042-01882042-01962015-08-01610.1177/2042018815579020Effect of zoledronic acid on serum calcium in Paget’s disease patients after educational strategies to improve calcium and vitamin D supplementationJoseph R. TucciHenry G. BoneGuoqin SuMonique TanZafer E. OzturkPaul AftringObjective: Bisphosphonates are the most effective therapeutic agents in patients with Paget’s disease of bone. As a result of their inhibition of osteoclastic activity, hypocalcemia of variable frequency and severity following intravenous bisphosphonate therapy has been reported. The present study assessed the effect of physician and patient education on adequate supplementation of calcium and vitamin D to reduce the potential risk of developing hypocalcemia following infusion of 5 mg zoledronic acid. Methods: This was an open-label, multicenter, controlled registry trial in which patients with Paget’s disease were treated with a single intravenous infusion of zoledronic acid. Physicians were provided with educational materials focusing on optimization of calcium and vitamin D supplementation following zoledronic infusion that they used to educate their patients. The primary safety variable was the percentage of patients with serum calcium level <2.07mmol/l 9–11 days after zoledronic acid infusion. Results: A total of 75 patients were evaluable in the post dose hypocalcemia safety analysis. Of these, only 1 patient had treatment-emergent hypocalcemia, with a serum calcium level of 1.92 mmol/l 4 days following therapy. Hypocalcemia-related symptoms were not reported in this patient and the serum calcium returned to normal range at 2.17 mmol/l within 1 week on oral calcium supplementation. Conclusions: These results suggest that, with optimization of calcium and vitamin D supplementation by physician and patient education, hypocalcemia is an infrequent occurrence following zoledronic acid infusion.https://doi.org/10.1177/2042018815579020 |
| spellingShingle | Joseph R. Tucci Henry G. Bone Guoqin Su Monique Tan Zafer E. Ozturk Paul Aftring Effect of zoledronic acid on serum calcium in Paget’s disease patients after educational strategies to improve calcium and vitamin D supplementation Therapeutic Advances in Endocrinology and Metabolism |
| title | Effect of zoledronic acid on serum calcium in Paget’s disease patients after educational strategies to improve calcium and vitamin D supplementation |
| title_full | Effect of zoledronic acid on serum calcium in Paget’s disease patients after educational strategies to improve calcium and vitamin D supplementation |
| title_fullStr | Effect of zoledronic acid on serum calcium in Paget’s disease patients after educational strategies to improve calcium and vitamin D supplementation |
| title_full_unstemmed | Effect of zoledronic acid on serum calcium in Paget’s disease patients after educational strategies to improve calcium and vitamin D supplementation |
| title_short | Effect of zoledronic acid on serum calcium in Paget’s disease patients after educational strategies to improve calcium and vitamin D supplementation |
| title_sort | effect of zoledronic acid on serum calcium in paget s disease patients after educational strategies to improve calcium and vitamin d supplementation |
| url | https://doi.org/10.1177/2042018815579020 |
| work_keys_str_mv | AT josephrtucci effectofzoledronicacidonserumcalciuminpagetsdiseasepatientsaftereducationalstrategiestoimprovecalciumandvitamindsupplementation AT henrygbone effectofzoledronicacidonserumcalciuminpagetsdiseasepatientsaftereducationalstrategiestoimprovecalciumandvitamindsupplementation AT guoqinsu effectofzoledronicacidonserumcalciuminpagetsdiseasepatientsaftereducationalstrategiestoimprovecalciumandvitamindsupplementation AT moniquetan effectofzoledronicacidonserumcalciuminpagetsdiseasepatientsaftereducationalstrategiestoimprovecalciumandvitamindsupplementation AT zafereozturk effectofzoledronicacidonserumcalciuminpagetsdiseasepatientsaftereducationalstrategiestoimprovecalciumandvitamindsupplementation AT paulaftring effectofzoledronicacidonserumcalciuminpagetsdiseasepatientsaftereducationalstrategiestoimprovecalciumandvitamindsupplementation |